Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study.

MLA

Roussel, Murielle, et al. “Bortezomib and High-Dose Melphalan Conditioning Regimen in Frontline Multiple Myeloma: An IFM Randomized Phase 3 Study.” Blood, vol. 139, no. 18, May 2022, pp. 2747–57. EBSCOhost, https://doi.org/10.1182/blood.2021014635.

APA

Roussel, M., Lauwers-Cances, V., Macro, M., Leleu, X., Royer, B., Hulin, C., Karlin, L., Perrot, A., Touzeau, C., Chrétien, M.-L., Rigaudeau, S., Dib, M., Nicolas-Virelizier, E., Escoffre-Barbe, M., Belhadj, K., Mariette, C., Stoppa, A.-M., Araujo, C., Doyen, C., … Attal, M. (2022). Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study. Blood, 139(18), 2747–2757. https://doi.org/10.1182/blood.2021014635

Chicago

Roussel, Murielle, Valérie Lauwers-Cances, Margaret Macro, Xavier Leleu, Bruno Royer, Cyrille Hulin, Lionel Karlin, et al. 2022. “Bortezomib and High-Dose Melphalan Conditioning Regimen in Frontline Multiple Myeloma: An IFM Randomized Phase 3 Study.” Blood 139 (18): 2747–57. doi:10.1182/blood.2021014635.